Abstract
Cancer biology as seen from chromosome 11 involves a plethora of mechanisms for chromosomal changes. The high frequency of repeated elements, the presence of active retrotransposons, the appearance of fragile sites, and the presence (and amplification) of drug resistance genes are all expected to destabilize the integrity of this chromosome. Thus, it is not unexpected that chromosome 11 is often mutated in a variety of tumors. Here, we review genes relevant to lung carcinogenesis and progression. Numerous loci and genes will be omitted since their role appears to be restricted to organ sites other than lung (i.e., the KAI gene at 11p11.2 which is involved in metastatic prostate cancer; the EXT2 gene at 11p11.2, which is one of the genes responsible for hereditary multiple exostoses; the WT1 gene at 11p13, which is frequently mutated in nephroblastoma; the TSG101 gene at 11p15.1-2, which may play a role in breast cancer; the ST5 (HTS1) gene at 11p15.3-4, which may be responsible for suppression of HeL a cell somatic cell hybrids). These genes may represent tissue-specific alterations that push certain types of cells into uncontrolled growth. In contrast, chromosome 11 also has genes for basic metabolic processes that are integral to the proliferation of cells (i.e., RRM1) and these are expected to be involved in a broad range of tumors. This review specifically focuses on HRAS, RRM1, MEN1, PPP2R1B, and ATM. Studies of the chromosomal abnormalities that underly cancer has produced a greater understanding of the normal patterns of gene regulation in healthy cells. Imprinting is one example of this, and the future promises to reveal much more.
Keywords: Lung Cancer, Chromosome 11, EXT2 gene, Nephroblastoma, Carcinogenesis, PPP2R1B, DUTT1, NCAM-related protein, LOH
Current Genomics
Title: The Pathogenesis of Lung Cancer and Chromosome 11
Volume: 1 Issue: 3
Author(s): Diana M. Pitterle, Young-Chul Kim, Youjia Cao, Ashish Gautam, Baohui Zhao, Amy Beck and Gerold Bepler
Affiliation:
Keywords: Lung Cancer, Chromosome 11, EXT2 gene, Nephroblastoma, Carcinogenesis, PPP2R1B, DUTT1, NCAM-related protein, LOH
Abstract: Cancer biology as seen from chromosome 11 involves a plethora of mechanisms for chromosomal changes. The high frequency of repeated elements, the presence of active retrotransposons, the appearance of fragile sites, and the presence (and amplification) of drug resistance genes are all expected to destabilize the integrity of this chromosome. Thus, it is not unexpected that chromosome 11 is often mutated in a variety of tumors. Here, we review genes relevant to lung carcinogenesis and progression. Numerous loci and genes will be omitted since their role appears to be restricted to organ sites other than lung (i.e., the KAI gene at 11p11.2 which is involved in metastatic prostate cancer; the EXT2 gene at 11p11.2, which is one of the genes responsible for hereditary multiple exostoses; the WT1 gene at 11p13, which is frequently mutated in nephroblastoma; the TSG101 gene at 11p15.1-2, which may play a role in breast cancer; the ST5 (HTS1) gene at 11p15.3-4, which may be responsible for suppression of HeL a cell somatic cell hybrids). These genes may represent tissue-specific alterations that push certain types of cells into uncontrolled growth. In contrast, chromosome 11 also has genes for basic metabolic processes that are integral to the proliferation of cells (i.e., RRM1) and these are expected to be involved in a broad range of tumors. This review specifically focuses on HRAS, RRM1, MEN1, PPP2R1B, and ATM. Studies of the chromosomal abnormalities that underly cancer has produced a greater understanding of the normal patterns of gene regulation in healthy cells. Imprinting is one example of this, and the future promises to reveal much more.
Export Options
About this article
Cite this article as:
Pitterle M. Diana, Kim Young-Chul, Cao Youjia, Gautam Ashish, Zhao Baohui, Beck Amy and Bepler Gerold, The Pathogenesis of Lung Cancer and Chromosome 11, Current Genomics 2000; 1 (3) . https://dx.doi.org/10.2174/1389202003351373
DOI https://dx.doi.org/10.2174/1389202003351373 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stroke and Neuroinflamation: Role of Sexual Hormones
Current Pharmaceutical Design Antiangiogenic Therapy
Current Pharmaceutical Design Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?
Current Drug Metabolism Foods and Drugs in the Management of Disease: A Case Study Comparing Omega-3 Fatty Acids and Aspirin for Inflammation
Current Pediatric Reviews P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry Chemical Modifications of Synthetic RNAi Agents and in vivo Delivery Techniques
Current Bioactive Compounds Perinatal Gene Transfer to the Liver
Current Pharmaceutical Design Rapid Characterization of a Novel Taspine Derivative-HMQ1611 Binding to EGFR by a Cell Membrane Chromatography Method
Combinatorial Chemistry & High Throughput Screening HR MAS MR Spectroscopy in Metabolic Characterization of Cancer
Current Topics in Medicinal Chemistry 25-hydroxyvitamin D Correlation with Prolactin Levels and Adenoma Size in Female Patients with Newly Diagnosed Prolactin Secreting Adenoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmaceutical Nanotechnology United States Patent Watch (April – June 2015)
Pharmaceutical Nanotechnology EDITORIAL(Hot Topic Integrated Therapeutic Approaches in the Treatment of Human Cancer)
Anti-Cancer Agents in Medicinal Chemistry Importance of Wnt Signaling in the Tumor Stroma Microenvironment
Current Cancer Drug Targets Estrogen(s) and Analogs as a Non-Immunogenic Endogenous Ligand in Targeted Drug/DNA Delivery
Current Medicinal Chemistry Novel Antitumor Strategies Using Cytokine PEDF for Prostate Cancer Therapy
Current Angiogenesis (Discontinued) Enzymatic Processing of <i>Omega</i> 3 Long Chain Polyunsaturated Fatty Acid Oils
Current Nutrition & Food Science MicroRNAs: Regulators of TLR2-Mediated Probiotic Immune Responses
MicroRNA Matrix Metalloproteinases as Valid Clinical Target
Current Pharmaceutical Design Editorial [Hot topic: Focal Adhesion Kinase Signaling in Cancer- Part II (Guest Editor: Vita M. Golubovskaya)]
Anti-Cancer Agents in Medicinal Chemistry Silver Nanoparticles with High Loading Capacity of Amphotericin B: Characterization, Bactericidal and Antifungal Effects
Current Drug Delivery